查看購物車
  • Simplified Chinese
  • English
  • Japanese
封面
市場調查報告書
商品編碼
1771583

美國Ultomiris 製藥市場規模、佔有率、趨勢分析報告：按適應症、最終用途、分銷管道、細分市場預測，2025-2033 年

U.S. Ultomiris Drug Market Size, Share & Trends Analysis Report By Indication (Paroxysmal Nocturnal Hemoglobinuria, Atypical Hemolytic Uremic Syndrome ), By End Use, By Distribution Channel, And Segment Forecasts, 2025 - 2033
出版日期: | 出版商: Grand View Research | 英文 150 Pages | 商品交期: 2-10個工作天內

價格

美國Ultomiris醫藥市場的規模與趨勢：

預計 2024 年美國Ultomiris Pharmaceuticals 市場規模為 14.6 億美元，到 2033 年將達到 81.4 億美元，2025 年至 2033 年的複合年成長率為 19.93%。

Ultomiris 因其延長的給藥間隔提高了患者的依從性和便利性，持續獲得認可，成為醫療保健提供者的首選。此外，重症肌無力 (gMG) 和視神經脊髓炎頻譜障礙 (NMOSD) 等臨床適應症的不斷增加也促進了市場的成長。

陣發性腎絲球腎炎 (PNH)、非典型溶血性尿毒症症候群 (aHUS) 和重症肌無力 (gMG) 等罕見自體免疫疾病和血液疾病的盛行率上升也在推動市場成長。例如，FDA 於 2022 年 4 月核准Ultomiris 用於治療抗乙醯膽鹼受體抗體陽性的 gMG 成年患者，擴大了 Ultomiris 的治療範圍並加強了其在神經病學領域的地位。此外，FDA 於 2024 年 3 月對 Ultomiris 用於治療視神經脊髓炎頻譜障礙 (NMOSD) 的優先審查支持了該公司強大的產品線。Astra Zeneca和 Alexion 的策略行銷，加上美國先進的醫療基礎設施和高診斷率，支持了市場的持續擴張。 Ultomiris 是一種每八週靜脈注射一次的長效 C5補體抑制劑，是治療補體介導疾病的合適藥物。

Ultomiris (ravulizumab-cwvz) 由 Alexion Pharmaceuticals 開發，並於 2021 年被Astra Zeneca收購，正在對美國罕見疾病市場產生巨大影響。 2024 年上半年，Ultomiris 在美國的銷售額為 10.32 億美元，較去年同期成長 27%。這一成長得益於適應症的擴大以及與其前身Soliris 的轉變。

在美國血液學市場，Ultomiris（ravulizumab）、Hemlibra（emicizumab）和Vafseo（vadadustat）在2023年貢獻了45%的銷售額成長。光是Ultomiris就貢獻了21%的成長，這得益於適應症擴大和核准的批准。

Astra Zeneca將ULTOMIRIS策略性擴展至視神經脊髓炎頻譜障礙 (NMOSD)，彰顯了其致力於拓展此藥物治療用途的承諾。 2024年3月，美國FDA核准Ultomiris用於治療視神經脊髓炎頻譜障礙 (NMOSD)，使其成為首個也是唯一一個用於此適應症的長效C5補體抑制劑。此次核准基於CHAMPION-NMOSD試驗，該試驗表明，接受ULTOMIRIS治療的患者在中位73週的治療期內未復發。

目錄

第1章調查方法與範圍

第2章執行摘要

第3章美國Ultomiris 藥物市場變數、趨勢與範圍

  • 市場展望
  • 市場動態
    • 市場促進因素分析
    • 市場限制因素分析
  • 商業環境分析
    • 產業分析-波特五力分析
    • PESTLE分析
    • 管道分析
    • 專利到期分析
    • 定價分析

第4章美國Ultomiris藥品市場：適應症業務分析

  • 2024年及2033年指示市場佔有率
  • 指示細分儀表板
  • 2021 年至 2033 年市場規模、預測與趨勢分析（按適應症）
  • 陣發性睡眠性血尿症（PNH）
  • 非典型溶血性尿毒症症候群（aHUS）
  • 全身性重症肌無力（gMG）
  • 視神經脊髓炎頻譜障礙 (NMOSD)

第5章美國Ultomiris 製藥市場：最終用途業務分析

  • 2024年及2033年最終用途市場佔有率
  • 最終用途細分儀表板
  • 按最終用途分類的市場規模、預測和趨勢分析（2021-2033 年）
  • 成人
  • 孩子們

第6章美國Ultomiris Pharmaceuticals市場：分銷通路業務分析

  • 2024年及2033年分銷通路市場佔有率
  • 分銷通路細分儀表板
  • 按分銷管道分類的市場規模、預測和趨勢分析（2021-2033 年）
  • 醫院藥房
  • 零售藥局
  • 網路藥局

第7章 競爭態勢

  • 參與者概覽
  • 企業市場分析
  • 公司分類
  • 戰略地圖
  • 公司簡介/上市公司
    • Alexion Pharmaceuticals（AstraZeneca）
Product Code: GVR-4-68040-622-5

U.S. Ultomiris Drug Market Size & Trends:

The U.S. ultomiris drug market size was estimated at USD 1.46 billion in 2024 and is projected to reach USD 8.14 billion by 2033, growing at a CAGR of 19.93% from 2025 to 2033. Ultomiris continues to gain traction due to its extended dosing interval, which improves patient compliance and convenience, making it a preferred choice among healthcare providers. In addition, its expanding clinical indications, including generalized myasthenia gravis (gMG) and neuromyelitis optica spectrum disorder (NMOSD), are contributing to market growth.

The rising prevalence of rare autoimmune and hematologic conditions, such as PNH, atypical hemolytic uremic syndrome (aHUS), and generalized myasthenia gravis (gMG), fuels market growth. For instance, the FDA's approval of Ultomiris for adults with anti-AChR antibody-positive gMG in April 2022 has expanded its therapeutic reach, strengthening its position in the neurology segment. In addition, the FDA's priority review in March 2024 for Ultomiris in neuromyelitis optica spectrum disorder (NMOSD) underscores its robust pipeline. Strategic marketing by AstraZeneca and Alexion, coupled with advanced medical infrastructure and high diagnosis rates in the U.S., supports sustained market expansion. The drug's role as a long-acting C5 complement inhibitor, administered intravenously every 8 weeks, positions it as a preferred choice for managing complement-mediated disorders.

Ultomiris (ravulizumab-cwvz), developed by Alexion Pharmaceuticals and acquired by AstraZeneca in 2021, has significantly impacted the U.S. rare disease market. In the first half of 2024, Ultomiris generated USD 1.032 billion in U.S. sales, marking a 27% increase over the previous year. This growth is attributed to expanding indications and a shift from its predecessor, Soliris.

In the U.S. hematological disorders market, Ultomiris (ravulizumab), Hemlibra (emicizumab), and Vafseo (vadadustat) collectively contributed 45% of the market's sales growth in 2023. Ultomiris alone accounted for 21% of this growth, driven by its expanded indications and regulatory approvals.

AstraZeneca's strategic expansion of Ultomiris into neuromyelitis optica spectrum disorder (NMOSD) underscores its commitment to broadening the drug's therapeutic applications. In March 2024, the U.S. FDA approved Ultomiris for NMOSD, making it the first and only long-acting C5 complement inhibitor for this indication. The approval was based on the CHAMPION-NMOSD trial, which demonstrated zero relapses among patients treated with Ultomiris over a median duration of 73 weeks.

U.S. Ultomiris Drug Market Report Segmentation

This report forecasts revenue growth in the U.S. and provides an analysis of the latest industry trends in each of the sub-segments from 2021 to 2033. For this study, Grand View Research has segmented the U.S. Ultomiris drug market report based on indication, end use, distribution channel, and region:

  • Indication Outlook (Revenue, USD Million, 2021 - 2033)
  • Paroxysmal Nocturnal Hemoglobinuria (PNH)
  • Atypical Hemolytic Uremic Syndrome (aHUS)
  • Generalized Myasthenia Gravis (gMG)
  • Neuromyelitis Optica Spectrum Disorder (NMOSD)
  • End Use Outlook (Revenue, USD Million, 2021 - 2033)
  • Adult
  • Pediatric
  • Distribution Channel Outlook (Revenue, USD Million, 2021 - 2033)
  • Hospital Pharmacies
  • Retail Pharmacies
  • Online Pharmacies

Table of Contents

Chapter 1. Methodology and Scope

  • 1.1. Market Segmentation & Scope
  • 1.2. Segment Definitions
    • 1.2.1. Indication
    • 1.2.2. End Use
    • 1.2.3. Distribution Channel
  • 1.3. Estimates and Forecast Timeline
  • 1.4. Research Methodology
  • 1.5. Information Procurement
    • 1.5.1. Purchased Database
    • 1.5.2. GVR's Internal Database
    • 1.5.3. Secondary Sources
    • 1.5.4. Primary Research
  • 1.6. Information Analysis
    • 1.6.1. Data Analysis Models
  • 1.7. Market Formulation & Data Visualization
  • 1.8. Model Details
    • 1.8.1. Commodity Flow Analysis
  • 1.9. List of Secondary Sources
  • 1.10. Objectives

Chapter 2. Executive Summary

  • 2.1. Market Snapshot
  • 2.2. Segment Snapshot
  • 2.3. Competitive Landscape Snapshot

Chapter 3. U.S. Ultomiris Drug Market Variables, Trends, & Scope

  • 3.1. Market Lineage Outlook
  • 3.2. Market Dynamics
    • 3.2.1. Market Driver Analysis
    • 3.2.2. Market Restraint Analysis
  • 3.3. Business Environment Analysis
    • 3.3.1. Industry Analysis - Porter's Five Forces Analysis
      • 3.3.1.1. Supplier Power
      • 3.3.1.2. Buyer Power
      • 3.3.1.3. Substitution Threat
      • 3.3.1.4. Threat of New Entrants
      • 3.3.1.5. Competitive Rivalry
    • 3.3.2. PESTLE Analysis
    • 3.3.3. Pipeline Analysis
    • 3.3.4. Patent Expiry Analysis
    • 3.3.5. Pricing Analysis

Chapter 4. U.S. Ultomiris Drug Market: Indication Business Analysis

  • 4.1. Indication Market Share, 2024 & 2033
  • 4.2. Indication Segment Dashboard
  • 4.3. Market Size & Forecasts and Trend Analysis, by Indication, 2021 to 2033 (USD Million)
  • 4.4. Paroxysmal Nocturnal Hemoglobinuria (PNH)
    • 4.4.1. Paroxysmal Nocturnal Hemoglobinuria (PNH) Market, 2021 - 2033 (USD Million)
  • 4.5. Atypical Hemolytic Uremic Syndrome (aHUS)
    • 4.5.1. Atypical Hemolytic Uremic Syndrome (aHUS) Market, 2021 - 2033 (USD Million)
  • 4.6. Generalized Myasthenia Gravis (gMG)
    • 4.6.1. Generalized Myasthenia Gravis (gMG) Market, 2021 - 2033 (USD Million)
  • 4.7. Neuromyelitis Optica Spectrum Disorder (NMOSD)
    • 4.7.1. Neuromyelitis Optica Spectrum Disorder (NMOSD) Market, 2021 - 2033 (USD Million)

Chapter 5. U.S. Ultomiris Drug Market: End Use Business Analysis

  • 5.1. End Use Market Share, 2024 & 2033
  • 5.2. End Use Segment Dashboard
  • 5.3. Market Size & Forecasts and Trend Analysis, by End Use, 2021 to 2033 (USD Million)
  • 5.4. Adult
    • 5.4.1. Adult Market, 2021 - 2033 (USD Million)
  • 5.5. Pediatric
    • 5.5.1. Pediatric Market, 2021 - 2033 (USD Million)

Chapter 6. U.S. Ultomiris Drug Market: Distribution Channel Business Analysis

  • 6.1. Distribution Channel Market Share, 2024 & 2033
  • 6.2. Distribution Channel Segment Dashboard
  • 6.3. Market Size & Forecasts and Trend Analysis, by Distribution Channel, 2021 to 2033 (USD Million)
  • 6.4. Hospital Pharmacies
    • 6.4.1. Hospital Pharmacies Market, 2021 - 2033 (USD Million)
  • 6.5. Retail Pharmacies
    • 6.5.1. Retail Pharmacies Market, 2021 - 2033 (USD Million)
  • 6.6. Online Pharmacies
    • 6.6.1. Online Pharmacies Market, 2021 - 2033 (USD Million)

Chapter 7. Competitive Landscape

  • 7.1. Participant Overview
  • 7.2. Company Market Position Analysis
  • 7.3. Company Categorization
  • 7.4. Strategy Mapping
  • 7.5. Company Profiles/Listing
    • 7.5.1. Alexion Pharmaceuticals (AstraZeneca)
      • 7.5.1.1. Overview
      • 7.5.1.2. Financial Performance
      • 7.5.1.3. Product Benchmarking
      • 7.5.1.4. Strategic Initiatives

List of Tables

  • Table 1 List of secondary sources
  • Table 2 List of abbreviations
  • Table 3 U.S. Ultomiris Drug market, by indication, 2021 - 2033 (USD Million)
  • Table 4 U.S. Ultomiris Drug market, by end use, 2021 - 2033 (USD Million)
  • Table 5 U.S. Ultomiris Drug market, by distribution channel, 2021 - 2033 (USD Million)

List of Figures

  • Fig. 1 Ultomiris Drug market segmentation
  • Fig. 2 Market research process
  • Fig. 3 Data triangulation techniques
  • Fig. 4 Primary research pattern
  • Fig. 5 Market research approaches
  • Fig. 6 Value-chain-based sizing & forecasting
  • Fig. 7 Market formulation & validation
  • Fig. 8 Market snapshot
  • Fig. 9 Therapeutic approach and application outlook (USD Million)
  • Fig. 10 Competitive landscape
  • Fig. 11 Ultomiris Drug market dynamics
  • Fig. 12 Ultomiris Drug market: Porter's five forces analysis
  • Fig. 13 Ultomiris Drug market: PESTLE analysis
  • Fig. 14 Indication market, 2021 - 2033 (USD Million)
  • Fig. 15 Paroxysmal Nocturnal Hemoglobinuria (PNH) market, 2021 - 2033 (USD Million)
  • Fig. 16 Atypical Hemolytic Uremic Syndrome (aHUS) market, 2021 - 2033 (USD Million)
  • Fig. 17 Generalized Myasthenia Gravis (gMG) market, 2021 - 2033 (USD Million)
  • Fig. 18 Neuromyelitis Optica Spectrum Disorder (NMOSD) market, 2021 - 2033 (USD Million)
  • Fig. 19 End Use market, 2021 - 2033 (USD Million)
  • Fig. 20 Adult market, 2021 - 2033 (USD Million)
  • Fig. 21 Pediatric market, 2021 - 2033 (USD Million)
  • Fig. 22 Distribution Channel market, 2021 - 2033 (USD Million)
  • Fig. 23 Hospital Pharmacies market, 2021 - 2033 (USD Million)
  • Fig. 24 Retail Pharmacies market, 2021 - 2033 (USD Million)
  • Fig. 25 Online Pharmacies market, 2021 - 2033 (USD Million)
  • Fig. 26 Company market position analysis
  • Fig. 27 Strategic framework